Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for mRNA-1403 in Norovirus vaccine. The expected timing is based on the latest available company guidance and may change.
Nova 301 Trial: 9/30/24- First participant dosed. 11/20/25- Enrolling second Northern Hemisphere season: 2025–2026. Interim analysis in 2026.
Verification
Confirm timing and program details against the company announcement or filing.